GENE THERAPY. REDEFINED.
Live / Applied — First extension granted (statement of use) (as of 19 Dec 2025)
What this means for you
Not registered yet, but its 21 Jun 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98612779
- Mark type
- Stylized text
- Filed
- 21 Jun 2024
- Published for opposition
- 13 May 2025
- Attorney of record
- Monica Riva Talley
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for gene therapy for the treatment of chronic diseases, cancer, or infectious diseases, namely, metabolic, endocrine, ophthalmic, oncological, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, hepatological, respiratory, viral, neurological, gastrointestinal, hormonal, dermatological, and immune-system-related diseases and disorders; pharmaceutical preparations for the treatment of chronic diseases, cancer, or infectious diseases, namely, metabolic, endocrine, ophthalmic, oncological, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, hepatological, respiratory, viral, neurological, gastrointestinal, hormonal, dermatological, and immune-system-related diseases and disorders
- Class 040 — Treatment of materials: Biomanufacturing for others, namely, manufacturing of pharmaceuticals using biological organisms in the manufacturing process; providing technical information in the field of pharmaceutical manufacturing
- Class 042 — Scientific and technological services: Testing, inspection, research, or development of pharmaceutical preparations for gene therapy; research and development in the pharmaceutical and biotechnology fields relating to the treatment of chronic diseases, cancer, or infectious diseases, namely, metabolic, endocrine, ophthalmic, oncological, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, hepatological, respiratory, viral, neurological, gastrointestinal, hormonal, dermatological, and immune system related diseases and disorders
Owner
- Kriya Therapeutics, Inc., Morrisville, NC, US
- Kriya Therapeutics, Inc., Morrisville, NC, US
Prosecution history
- 20 Dec 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 19 Dec 2025 — SOU EXTENSION 1 GRANTED
- 19 Dec 2025 — SOU EXTENSION 1 FILED
- 19 Dec 2025 — SOU TEAS EXTENSION RECEIVED
- 08 Jul 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 13 May 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 13 May 2025 — PUBLISHED FOR OPPOSITION
- 07 May 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 10 Apr 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 10 Apr 2025 — EXAMINER'S AMENDMENT ENTERED
- 10 Apr 2025 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 10 Apr 2025 — EXAMINERS AMENDMENT E-MAILED
- 10 Apr 2025 — EXAMINERS AMENDMENT -WRITTEN
- 16 Jan 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 16 Jan 2025 — NON-FINAL ACTION E-MAILED